B. Braun Melsungen AG

B. Braun Melsungen AG operates across medical devices, clinical nutrition, extracorporeal blood treatment, and surgical solutions at significant scale: approximately €9.4 billion in annual sales with over 64,000 employees spanning every continent. The company develops and manufactures infusion therapy systems, dialysis equipment, surgical instruments through its Aesculap division, and related medical technologies deployed in clinical settings worldwide.

In infusion systems, the company introduced the Braunüle in the 1950s - a single-use plastic cannula designed to improve both patient safety and ease of clinical use. Clinical nutrition products like Lipofundin (introduced 1962) address nutritional support in hospital and home care settings. Extracorporeal blood treatment equipment represents another core domain, with dialysis machines representing both technical complexity and high-volume deployment requirements across renal care facilities.

The Aesculap division focuses on surgical instruments and innovations, addressing the instrumentation requirements of operating rooms and surgical workflows. Across these domains, the company operates manufacturing and distribution infrastructure supporting both hospital systems and outpatient care settings globally. Founded in 1839 in Melsungen, Germany, the organization remains family-led and has maintained continuous R&D investment across its product categories.